Synapse - Works

Results (115370)

Evaluation of efficacy and fertility after non-radical surgical therapy (extra fascial hysterectomy or cone biopsy with pelvic lymphadenectomy) for stage IA1 (LVSI+) and IA2-IB1 (GOG-278) cervical cancer

Meeting Abstract

Covens, A.; Huang, H.; Kim, Y. B.; Kim, M. H.; DiSilvestro, P.; Vicus, D.; Holman, L.; Fleury, A.; Pearson, J.; Thawani, N.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Durvalumab plus paclitaxel/carboplatin plus bevacizumab followed by durvalumab, bevacizumab plus olaparib maintenance among patients with newly-diagnosed advanced ovarian cancer without a tumor BRCA1/BRCA2 mutation: Updated results from DUO-O/ENGOT-OV46/GOG-3025 Trial

Meeting Abstract

Harter, P.; Wimberger, P.; Okamoto, A.; Reuss, A.; Lim, M. C.; Rubio-Pérez, M. J.; Vardar, M. A.; Scambia, G.; Trédan, O.; Hietanen, S.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Mainstreaming in gynecologic oncology clinics triples the odds of genetic testing among patients with epithelial ovarian cancer

Meeting Abstract

Sia, T.; Byrne, M.; Fong, C.; Khurram, A.; Zhou, Q.; Saban, S.; Wu, M.; Varice, N.; Hamilton, J.; Carrot Zhang, J.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Progression-free and overall survival in newly-diagnosed homologous recombination DNA-repair deficient ovarian cancer without a BRCA mutation

Meeting Abstract

Graves, S.; Sullivan, M.; Adkoli, A.; Zhou, Q.; Chi, D.; Ellenson, L.; O'Cearbhaill, R.; Weigelt, B.; Grisham, R.
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Evaluation of physical function and quality of life before and after non-radical surgical therapy (extra fascial hysterectomy or cone biopsy with pelvic lymphadenectomy) for stage IA1 (LVSI+) and IA2-IB1 cervical cancer (GOG-278)

Meeting Abstract

Covensa, A.; Huang, H.; Kim, Y. B.; Kim, M. H.; Stuckey, A.; Vicus, D.; Holman, L.; Fleury, A.; Pearson, J.; Thawani, N.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Avutometinib plus defactinib in recurrent low-grade serous ovarian cancer: A subgroup analysis of ENGOT-OV60/GOG-3052/ RAMP 201 Part A

Meeting Abstract

Banerjee, S.; Van Nieuwenhuysen, E.; Santin, A.; Ring, K.; Colombo, N.; Thaker, P.; Prendergast, E.; Clamp, A.; Ray-Coquard, I.; Chon, H. S.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Clinical activity of tazemetostat, an EZH2 inhibitor, among patients with advanced endometrioid endometrial cancer and ovarian clear cell carcinoma with and without ARID1A mutations (NRG-GY014)

Meeting Abstract

Schram, A.; Eskander, R.; Sill, M.; Hagemann, A.; Waggoner, S.; Press, J.; Ghamande, S.; Zivanovic, O.; Bottsford-Miller, J.; Aghajanian, C.
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Response to treatment with nab-Sirolimus in patients with perivascular epithelioid cell sarcoma of gynecologic or peritoneal origin: Subgroup analysis from AMPECT

Meeting Abstract

Herzog, T.; Dockery, L.; Dickson, M.; Ganjoo, K.; Ravi, V.; Ding, L.; Schmid, A.; Palma, N.; Navarro, W.; Wagner, A.
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Opportunistic salpingectomy during gynecologic and non-gynecologic abdominopelvic procedures for ovarian cancer primary prevention: A cost-effectiveness analysis

Meeting Abstract

Adjei, N.; Yeh, P.; Haas, A.; Zhao, H.; Stone, R.; Roche, K. L.; Lu, K.; Sun, C.; Toumazis, I.; Meyer, L.
Gynecologic Oncology (2024)

Fulltext@MSK | Save

Overall survival and progression-free survival by PD-L1 status among endometrial cancer patients treated with pembrolizumab plus carboplatin/paclitaxel as compared to carboplatin/paclitaxel plus placebo in the NRG GY018 trial

Meeting Abstract

Eskander, R.; Sill, M.; Beffa, L.; Moore, R.; Hope, J.; Musa, F.; Mannel, R.; Shahin, M.; Cantuaria, G.; Girda, E.; more...
Gynecologic Oncology (2024)

Fulltext@MSK | Save